24.01.2024 - Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) investors concerning the Company’s . Seite 1
18.01.2024 - Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023. BioNTech is a biotechnology .
06.11.2023 - Positive clinical data updates across multiple drug classes including antibody-drug conjugate (ADC) candidates BNT323/DB-1303, BNT325/DB-1305, CAR-T candidate BNT211, T cell therapy candidate BNT221 and mRNA cancer vaccine candidate BNT116Progress .
It's time to see what Germany searched for on Google throughout 2021. While coronavirus continued to dominate daily life, it seems like sports is what was o.
Die BioNTech-Aktie (WKN: A2PSR2) hat in den vergangenen Monaten eine fast schon beispiellose Rally aufs Börsenparkett gelegt. Da war es nur eine Frage der Zeit, bis es mal zu einem Rücksetzer kommen würde. In den letzten Tagen war es dann so weit. Nachdem am 10.08. das vorläufige Rekordhoch von f.